Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Duration of androgen deprivation therapy and nadir of testosterone at 20 ng/dL predict testosterone recovery to supracastrate level in prostate cancer patients who received external beam radiotherapy.
Takei A, Sakamoto S, Wakai K, Tamura T, Imamura Y, Xu M, Maimaiti M, Kawamura K, Imamoto T, Komiya A, Akakura K, Ichikawa T. Takei A, et al. Among authors: maimaiti m. Int J Urol. 2018 Apr;25(4):352-358. doi: 10.1111/iju.13521. Epub 2018 Jan 11. Int J Urol. 2018. PMID: 29323427
Biparametric Prostate Imaging Reporting and Data System version2 and International Society of Urological Pathology Grade Predict Biochemical Recurrence after Radical Prostatectomy.
Takeuchi N, Sakamoto S, Nishiyama A, Horikoshi T, Yamada Y, Iizuka J, Maimaiti M, Imamura Y, Kawamura K, Imamoto T, Komiya A, Ikehara Y, Akakura K, Ichikawa T. Takeuchi N, et al. Among authors: maimaiti m. Clin Genitourin Cancer. 2018 Aug;16(4):e817-e829. doi: 10.1016/j.clgc.2018.02.011. Epub 2018 Feb 24. Clin Genitourin Cancer. 2018. PMID: 29576444
Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer.
Sakamoto S, Maimaiti M, Xu M, Kamada S, Yamada Y, Kitoh H, Matsumoto H, Takeuchi N, Higuchi K, Uchida HA, Komiya A, Nagata M, Nakatsu H, Matsuyama H, Akakura K, Ichikawa T. Sakamoto S, et al. Among authors: maimaiti m. J Clin Med. 2019 Apr 11;8(4):489. doi: 10.3390/jcm8040489. J Clin Med. 2019. PMID: 30978937 Free PMC article.
Functional analysis of LAT3 in prostate cancer: Its downstream target and relationship with androgen receptor.
Rii J, Sakamoto S, Sugiura M, Kanesaka M, Fujimoto A, Yamada Y, Maimaiti M, Ando K, Wakai K, Xu M, Imamura Y, Shindo N, Hirota T, Kaneda A, Kanai Y, Ikehara Y, Anzai N, Ichikawa T. Rii J, et al. Among authors: maimaiti m. Cancer Sci. 2021 Sep;112(9):3871-3883. doi: 10.1111/cas.14991. Epub 2021 Jul 8. Cancer Sci. 2021. PMID: 34050700 Free PMC article.
Identification of AR-V7 downstream genes commonly targeted by AR/AR-V7 and specifically targeted by AR-V7 in castration resistant prostate cancer.
Sugiura M, Sato H, Okabe A, Fukuyo M, Mano Y, Shinohara KI, Rahmutulla B, Higuchi K, Maimaiti M, Kanesaka M, Imamura Y, Furihata T, Sakamoto S, Komiya A, Anzai N, Kanai Y, Luo J, Ichikawa T, Kaneda A. Sugiura M, et al. Among authors: maimaiti m. Transl Oncol. 2021 Jan;14(1):100915. doi: 10.1016/j.tranon.2020.100915. Epub 2020 Oct 20. Transl Oncol. 2021. PMID: 33096335 Free PMC article.
The heavy chain of 4F2 antigen promote prostate cancer progression via SKP-2.
Maimaiti M, Sakamoto S, Sugiura M, Kanesaka M, Fujimoto A, Matsusaka K, Xu M, Ando K, Saito S, Wakai K, Imamura Y, Nakayama K, Kanai Y, Kaneda A, Ikehara Y, Ikeda JI, Anzai N, Ichikawa T. Maimaiti M, et al. Sci Rep. 2021 Jun 1;11(1):11478. doi: 10.1038/s41598-021-90748-9. Sci Rep. 2021. PMID: 34075107 Free PMC article.
69 results